Delving into the Latest Updates on RDc001 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

RDc001

Target-

Action-

Mechanism-

Therapeutic Areas

NeoplasmsHemic and Lymphatic Diseases

Active Indication

Advanced Malignant Solid NeoplasmHematologic Neoplasms

Inactive Indication-

Originator Organization

Henan Ruida Pharmaceutical Technology Co., Ltd.

Active Organization

Henan Ruida Pharmaceutical Technology Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

[Translation] An open-label, multicenter, dose-escalation and dose-expansion Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of RDc001 tablets in patients with relapsed/refractory hematologic malignancies and advanced solid tumors

主要目的 1. 评价RDc001片在复发/难治血液瘤及晚期实体瘤患者中的安全性和耐受性。 2. 观察可能出现的RDc001片的剂量限制性毒性（DLT）。 3. 确定最大耐受剂量（MTD）和/或II期推荐剂量（RP2D）。次要目的 1. 评价RDc001片在复发/难治血液瘤及晚期实体瘤患者中的药代动力学特征。 2. 评价RDc001片的初步抗肿瘤疗效。

[Translation]

Primary Objectives 1. Evaluate the safety and tolerability of RDc001 tablets in patients with relapsed/refractory hematologic malignancies and advanced solid tumors. 2. Observe for potential dose-limiting toxicities (DLTs) of RDc001 tablets. 3. Determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D). Secondary Objectives 1. Evaluate the pharmacokinetic profile of RDc001 tablets in patients with relapsed/refractory hematologic malignancies and advanced solid tumors. 2. Evaluate the preliminary antitumor efficacy of RDc001 tablets.

Start Date-

Sponsor / Collaborator

Henan Ruida Pharmaceutical Technology Co., Ltd.

100 Clinical Results associated with RDc001

Login to view more data

100 Translational Medicine associated with RDc001

Login to view more data

100 Patents (Medical) associated with RDc001

Login to view more data

100 Deals associated with RDc001

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 1	China	Henan Ruida Pharmaceutical Technology Co., Ltd.	12 Aug 2025
Hematologic Neoplasms	Phase 1	China	Henan Ruida Pharmaceutical Technology Co., Ltd.	12 Aug 2025